PeptidePedia The community reference

Contributions of DPP4_Dagmar

User contributions·24 logged edits·page 1 of 1

Contributions by DPP4_Dagmar, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,533 edits includes activity predating the current log.

  1. 12:27, 25 Jun 2026 (diff | hist) Peptide supply chain 8,410 ±0 expand §Handovers, and why they are where things go missing
  2. 13:31, 20 Jun 2026 (diff | hist) Fmoc chemistry 4,618 ±0 correct the freezer temperature range given for long-term storage
  3. 01:31, 10 Apr 2026 (diff | hist) Glucose-dependent insulinotropic polypeptide 8,265 ±0 split overlong sentence
  4. 09:30, 6 Mar 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 822 +119 /* Is GLP-1(9-36) inert or not? */ reply
  5. 08:44, 5 Mar 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 400 +261 /* Is GLP-1(9-36) inert or not? */ new section
  6. 13:25, 4 Mar 2026 (diff | hist) Talk:List of GLP-1 receptor agonists 611 +80 /* Excluding DPP-4 inhibitors */ reply
  7. 00:19, 28 Jan 2026 (diff | hist) AmbioPharm 13,446 +55 expand §Reception
  8. 09:12, 25 Jan 2026 (diff | hist) Talk:Liraglutide 822 +109 /* DPP-4 resistance: the article contradicted itself */ reply
  9. 10:05, 24 Jan 2026 (diff | hist) Talk:Liraglutide 400 +210 /* DPP-4 resistance: the article contradicted itself */ new section
  10. 00:30, 20 Jan 2026 (diff | hist) Satiety signalling 5,593 ±0 convert the receptor-distribution list to a table
  11. 21:23, 11 Jan 2026 (diff | hist) Beta cell function 6,096 ±0 ce per PP:MOS
  12. 00:00, 24 Oct 2025 (diff | hist) Shenzhen Hybio Pharmaceutical 9,295 +1,143 correct the trading name — the short code and the legal name are different things
  13. 11:54, 27 Sep 2025 (diff | hist) Arcuate nucleus 5,251 +234 expand §Relevance to incretin pharmacology
  14. 19:02, 2 Aug 2025 (diff | hist) Receptor bias 4,000 ±0 state that the enzyme inhibitor class works by raising endogenous levels
  15. 04:37, 27 Jun 2025 (diff | hist) Sigma-Aldrich (Shanghai) Trading 8,283 +645 m add the research-use-only statement to the lead rather than only the footer
  16. 13:42, 19 May 2025 (diff | hist) Custom peptide synthesis 4,512 +735 m add the excursion tolerance with the study it derives from
  17. 11:19, 19 Feb 2025 (diff | hist) Insulin secretion 5,442 +887 add the reference range with the assay it was established on
  18. 09:25, 16 Feb 2025 (diff | hist) Glucagon-like peptide-1 10,192 +175 add the counter-regulatory glucagon point, sourced
  19. 16:47, 7 Feb 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 6,686 +455 m ce, tighten prose
  20. 09:39, 5 Feb 2025 (diff | hist) Solid-phase peptide synthesis 4,279 ±0 m add the stopper material, since it affects moisture ingress
  21. 05:46, 2 Jan 2025 (diff | hist) Orforglipron 2,903 +548 expand §Reported clinical findings
  22. 12:02, 6 Nov 2024 (diff | hist) GLP-1 receptor 5,068 +204 the numbers in the lead disagreed with the body; body was right
  23. 04:08, 6 Sep 2024 (diff | hist) Albumin binding half-life extension 2,425 ±0 m give the magnitude of the incretin effect as a percentage of the insulin response
  24. 17:56, 29 Jul 2024 (diff | hist) Enteroendocrine L cell 2,224 ±0 m the numbers in the lead disagreed with the body; body was right